Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) – Analysts at HC Wainwright issued their FY2024 earnings estimates for shares of Kezar Life Sciences in a report issued on Thursday, March 16th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($1.19) per share for the year. HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($1.25) per share.
Several other research firms also recently commented on KZR. Wells Fargo & Company reduced their price target on shares of Kezar Life Sciences from $17.00 to $14.00 and set an “overweight” rating for the company in a research report on Tuesday, January 3rd. William Blair reiterated a “market perform” rating on shares of Kezar Life Sciences in a research report on Wednesday.
Kezar Life Sciences Stock Down 1.6 %
Insiders Place Their Bets
In other Kezar Life Sciences news, major shareholder Morningside Venture Investment sold 5,000 shares of the company’s stock in a transaction on Thursday, January 12th. The shares were sold at an average price of $6.77, for a total transaction of $33,850.00. Following the completion of the transaction, the insider now owns 5,881,078 shares in the company, valued at approximately $39,814,898.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders sold 248,276 shares of company stock worth $1,708,683. 7.80% of the stock is owned by insiders.
Hedge Funds Weigh In On Kezar Life Sciences
A number of large investors have recently bought and sold shares of the company. Bayesian Capital Management LP purchased a new position in shares of Kezar Life Sciences in the 3rd quarter valued at about $248,000. ProShare Advisors LLC purchased a new position in shares of Kezar Life Sciences in the 3rd quarter valued at about $100,000. E Fund Management Co. Ltd. purchased a new position in shares of Kezar Life Sciences in the 3rd quarter valued at about $145,000. Trexquant Investment LP increased its holdings in shares of Kezar Life Sciences by 173.8% in the 2nd quarter. Trexquant Investment LP now owns 98,187 shares of the company’s stock valued at $812,000 after purchasing an additional 62,326 shares in the last quarter. Finally, Occudo Quantitative Strategies LP purchased a new position in shares of Kezar Life Sciences in the 2nd quarter valued at about $778,000. Hedge funds and other institutional investors own 84.03% of the company’s stock.
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.
- Get a free copy of the StockNews.com research report on Kezar Life Sciences (KZR)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.